The main research field of our group is pharmacoepidemiology and pharmacovigilance, with a special focus on the patterns of medicines utilization, effectiveness and adverse effects in real world.
The group is a Special Group of Research recognized by AGAUR GenCat, and is a partner of the European Consortium “EU PE&PV Network”. The group together with the Preventive medicine group has become a member of the VAccine monitoring Collaboration for Europe network for the study the safety and efficacy of vaccines in Europe.
The group has continued its participation in the “Genomics of COVID-19 vaccine-induced GBS, VITT/TTS and miocarditis/pericarditis” project. In 2023 we has initiated with IDIAPJgol and other researchers an PERIS awarded project focused on use of medicines in pregnant women and outcomes.
Our group has continued the international training activities through its participation in the European master of pharmacoepidemiology and hosting fellow researchers.
eCORE
- Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation
- Global Health
Team
Group Leader
Maria Antònia Agustí Escasany
Principal Investigator (PI)
Immaculada Danés Carreras, Mònica Sabaté Gallego, Cristina Aguilera Martín
Researchers
Montserrat Bosch Ferrer, Lina Camacho Arteaga, Eduard Diogène Fadini, Eulàlia Pérez Esquirol, Elena Ballarín Alins, Lourdes Vendrell Bosch, Angela Mesas Idáñez, Francisco Javier Medel
PhD Students
Carla Sans Pola, Judit Riera Arnau, Carolina Iglesias López, Kristopher Amaro Hosey, Lina Leguizamo Martínez, Gustavo Molina Molina, Elena Guillen Benítez, Emilie Anderssen Nordalh, Manuel Machado, Lucia Bellas Fernández, Daniel Wang, Marta Merino Castelló
Publications
Agustí A, Cereza G, de Abajo FJ, Maciá MA. Sacristán JA.
Clinical pharmacology facing the real-world setting: pharmacovigilance, pharmacoepidemiology and the economic evaluation of drugs.
Pharmacol Res 2023;197:1-9.
DOI: 10.1016/j.phrs.2023.106967
IF: 9.3
Filippi-Arriaga F, Aguilera C, Guillén E, Bellas L, Pérez E, Vendrell L, Agustí A, Cereza G
Unknown adverse drug reactions from spontaneous reports in a hospital setting: characterization, follow-up, and contribution to the pharmacovigilance system.
Front Pharmacol 2023:1-11.
DOI: 10.3389/fphar.2023.1211786
IF: 5.6
Abtahi S, Pajouheshnia R, Durán CE, Riera-Arnau J, Gamba M, Alsina E, Hoxhaj V, Andersen M, Bartolini C, Brøgger Kristiansen S, Brown J, Erikstrup Hallgreen Ch, García-Poza P, Gardarsdottir H, Gini R, Girardi A, Holthuis E, Huerta C, Ibáñez L, Limoncella G, Martín-Pérez M, Paoletti O, Roberto G, Souverein P, Swart K, Wing K, Sturkenboom M, Klungel O.
Impact of 2018 EU risk minimisation measures and revised pregnancy prevention programme on utilisation and prescribing trends of medicinal products containing valproate: an interrupted time series study
Drug Safety 2023:1-14.
DOI: 10.1007/s40264-023-01314-3
IF: 4.2
Corominas J, Garriga C, Prenafeta A, Moros A, et al.
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.
The Lancet Regional Health – Europe 2023:1-27
DOI: 10.1101/2022.07.05.22277210
IF: 20.9
Iglesias-López C, Agustí A, Vallano A, Obach M.
Financing and reimbursement of approved advanced therapies in several European countries.
Value in Health 2023:1-37.
DOI: 10.1016/j.val.2022.12.014
IF: 4.5
Projects
Detection of false positives in patients with an electronic beta-lactam allergy alert in their medical records
Principal Investigator: Victòria Cardona Dahl
Agency: ISCIII-FIS
Funding: 36,330 €
Period: 2020-2024
COVID-19 infection and medicines in pregnancy – a multinational registry based study Medication use in pregnant women with COVID-19 (EMA/2018/28PE No4).
Principal Investigator: Olaf Klungel, Miriam Sturkenboom (UU, UMC), Hedvig Nordeng (UO).
Agency: EMA
Funding: 548,890 €, allocated budget: 25,000 €.
Period: 2020-2023
Genomics of COVID-19 vaccine-induced GBS, VITT/TTS and miocarditis/pericarditis
Principal Investigator: Xavier Martínez, Mònica Sabaté
Agency: VAC4EU
Funding: 37,350 €
Period: 2022-2024
Uso de fármacos en mujeres embarazadas y lactantes. Consecuencias en la salud de estas mujeres y en la de su descendencia
Principal Investigator: Cristina Vèdia, Cristina Aguilera
Agency: Pla estratègic de recerca i innovació en salut (PERIS)
Funding: 150,964.95 €; locally 4,500 €
Period: 2022-2024
Optimización del tratamiento farmacológico en pacientes institucionalizados en residencias de Cataluña. Estudio cuasiexperimental antes y después.
Principal Investigator: Estrella Barceló Colomer, Emilie Anderssen Nordalh
Agency: Mutual mèdica
Funding: 25,000€
Period: 2022-2024
